L-DOPA regulates neuroinflammation and Aβ pathology through NEP and ADAM17 in a mouse model of AD
- PMID: 38685105
- PMCID: PMC11059733
- DOI: 10.1186/s13041-024-01092-8
L-DOPA regulates neuroinflammation and Aβ pathology through NEP and ADAM17 in a mouse model of AD
Abstract
Dopamine plays important roles in cognitive function and inflammation and therefore is involved in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD). Drugs that increase or maintain dopamine levels in the brain could be a therapeutic strategy for AD. However, the effects of dopamine and its precursor levodopa (L-DOPA) on Aβ/tau pathology in vivo and the underlying molecular mechanisms have not been studied in detail. Here, we investigated whether L-DOPA treatment alters neuroinflammation, Aβ pathology, and tau phosphorylation in 5xFAD mice, a model of AD. We found that L-DOPA administration significantly reduced microgliosis and astrogliosis in 5xFAD mice. In addition, L-DOPA treatment significantly decreased Aβ plaque number by upregulating NEP and ADAM17 levels in 5xFAD mice. However, L-DOPA-treated 5xFAD mice did not exhibit changes in tau hyperphosphorylation or tau kinase levels. These data suggest that L-DOPA alleviates neuroinflammatory responses and Aβ pathology but not tau pathology in this mouse model of AD.
Keywords: Alzheimer’s disease; Aβ; L-DOPA; Neuroinflammation; Tau.
© 2024. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures

Similar articles
-
The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and rescues synaptic/cognitive functions by modulating DRD1 signaling or directly binding to Abeta.J Neuroinflammation. 2024 Aug 11;21(1):200. doi: 10.1186/s12974-024-03180-x. J Neuroinflammation. 2024. PMID: 39129007 Free PMC article.
-
Ibrutinib modulates Aβ/tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimer's disease.Aging Cell. 2021 Mar;20(3):e13332. doi: 10.1111/acel.13332. Epub 2021 Mar 11. Aging Cell. 2021. PMID: 33709472 Free PMC article.
-
Erlotinib regulates short-term memory, tau/Aβ pathology, and astrogliosis in mouse models of AD.Front Immunol. 2024 Oct 7;15:1421455. doi: 10.3389/fimmu.2024.1421455. eCollection 2024. Front Immunol. 2024. PMID: 39434878 Free PMC article.
-
Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?Curr Alzheimer Res. 2016;13(4):403-12. doi: 10.2174/1567205013666151116125714. Curr Alzheimer Res. 2016. PMID: 26567742 Review.
-
Non-coding RNAs in the pathogenesis of Alzheimer's disease: β-amyloid aggregation, Tau phosphorylation and neuroinflammation.Mol Biol Rep. 2025 Jan 31;52(1):183. doi: 10.1007/s11033-025-10284-x. Mol Biol Rep. 2025. PMID: 39890684 Review.
Cited by
-
Association between the use of levodopa/carbidopa, Alzheimer's disease biomarkers, and cognitive decline among participants in the National Alzheimer's Coordinating Center Uniform Data Set.Alzheimers Dement. 2025 May;21(5):e70213. doi: 10.1002/alz.70213. Alzheimers Dement. 2025. PMID: 40356023 Free PMC article.
-
The role of L-DOPA in neurological and neurodegenerative complications: a review.Mol Cell Biochem. 2025 Jun 9. doi: 10.1007/s11010-025-05324-w. Online ahead of print. Mol Cell Biochem. 2025. PMID: 40488810 Review.
-
Gut microbiota and Parkinson's disease: potential links and the role of fecal microbiota transplantation.Front Aging Neurosci. 2024 Nov 29;16:1479343. doi: 10.3389/fnagi.2024.1479343. eCollection 2024. Front Aging Neurosci. 2024. PMID: 39679259 Free PMC article. Review.
-
Uric Acid: A Biomarker and Pathogenic Factor of Affective Disorders and Neurodegenerative Diseases.Curr Pharm Des. 2025;31(8):585-597. doi: 10.2174/0113816128333916241003180018. Curr Pharm Des. 2025. PMID: 39415583 Review.
References
-
- Zhang M, Ganz AB, Hulsman M, Netherlands Brain B, Rozemuller AJM, Scheltens P, Hoozemans JJ, Holstege H. Neuropathological hallmarks of Alzheimer’s disease in centenarians, in the context of aging. Alzheimers Dement. 2021;17(S3):e053600.
-
- Nobili A, Latagliata EC, Viscomi MT, Cavallucci V, Cutuli D, Giacovazzo G, Krashia P, Rizzo FR, Marino R, Federici M, et al. Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer’s disease. Nat Commun. 2017;8(1):14727. doi: 10.1038/ncomms14727. - DOI - PMC - PubMed
-
- Pike AF, Longhena F, Faustini G, van Eik JM, Gombert I, Herrebout MAC, Fayed M, Sandre M, Varanita T, Teunissen CE, et al. Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease. J Neuroinflammation. 2022;19(1):50. doi: 10.1186/s12974-022-02410-4. - DOI - PMC - PubMed
-
- Nam E, Derrick JS, Lee S, Kang J, Han J, Lee SJC, Chung SW, Lim MH. Regulatory Activities of Dopamine and Its Derivatives toward Metal-Free and Metal-Induced Amyloid-beta Aggregation, Oxidative Stress, and Inflammation in Alzheimer's Disease. ACS Chem Neurosci. 2018;9(11):2655–2666. doi: 10.1021/acschemneuro.8b00122. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous